Rosetta Genomics Ltd (ROSGQ)

[aetosellinas]

Great article- seeking alpha out

New cancer patients every year who may benefit from ROSG cancer miRNA tests: over 200,000
Medicare covered cost/test: $3500
Potential Medicare market: $700 Million
Conservatively estimate that ROSG captures 20% of this market: $140 million in revenues
ROSG splits the revenues with Precision Therapeutics (marketer of products in U.S.): $70 million in revenues
Subtract operating expenses (currently $8 million/year): $62 million in profits
Earnings per share (9.1 million shares): $6.85/share
Assign ROSG a price/earnings multiple of 5: $34.25/share


http://m.seekingalpha.com/article/1891811-recapping-recent-events-in-rosetta-genomics-2014-could-be-a-breakout-year?source=email_rt_article_readmore